Date: 2017-05-22
Type of information: Nomination
Compound: non-executive directors
Company: Atlantic Healthcare (UK)
Therapeutic area: Inflammatory diseases - Gastrointestinal diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On May 22, 2017, Atlantic Healthcare announced the strengthening of the Board for the next stage of the company’s development, with the appointments of William (Bill) Ringo and Andrew Boyce as non-executive directors. Additionally, Thomas Wellner has agreed to become Chairman of the Board, following his appointment as interim Chairman in April 2017.
- Bill steps up to the Board from his role as a U.S. commercial and corporate advisor to the company. Bill currently serves on the Boards of several NASDAQ-listed U.S.-based companies, including as Chairman of Assembly Biosciences, and as director of Sangamo Therapeutics , Immune Design, Dermira, and Five Prime Therapeutics. His previous leadership roles include Chairman and Interim Chief Executive Officer of InterMune (acquired by Roche) and Senior Vice President of Strategy and Business Development at Pfizer, overseeing its acquisition of Wyeth. Before joining Pfizer, he was President and Chief Executive Officer of NAbgenix, a biotechnology company acquired by Amgen, and, prior to this, a senior executive and member of Eli Lilly and Company’s operating committee.
- Andrew represents a significant family office shareholding in Atlantic Healthcare and was one of its founding investors in 2006. Since 1987, Andrew has managed a private family office, which has diverse commercial interests including technology and medical investments, property, and farming. He is a member of the board of UK AIM-listed Hardide plc, an advanced surface coating technology company, where he has served as a non-executive director since June 2012.
Financial terms:
Latest news:
Is general: Yes
